NEW YORK (GenomeWeb) – Clinical genomic testing firm MedGenome and Natera have reached an exclusive agreement to provide Natera's Panorama non-invasive prenatal test in India.
Under the terms of the agreement, MedGenome will have a license to develop the capacity of and to perform the test, which screens for trisomies, 21, 18, and 13, and certain sex chromosome abnormalities, such as monosomy X.
MedGenome CEO Sam Santhosh said in a statement that India has the largest number of babies born with chromosomal disorders in the world, about 130,000 each year. "Through our partnership with Natera, we hope to bring about significant changes in the way pregnancies are managed in India," he said.
MedGenome also will conduct a study of 1,000 women at high risk for chromosomal disease in the fetus, starting from 11 to 20 weeks of pregnancy, it said.
Financial and other terms of the deal were not disclosed.